Loading…

64676467.TWCompetitor analysis, valuation and peers

Taiwan · TWD·Health Care›Pharmaceuticals: Major
Mkt cap
$368M
US dollars, full cap
Free float
30%
of shares outstanding
$/day
$6.71M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
n/a
WACC 10.0%
Hurdle
n/a
no reverse DCF
Next earnings
14 days
2 Dec 2026
Close · TWDNT$224.50
1D-2.8%
1W-2.4%
1Mn/a
3Mn/a
6Mn/a
YTDn/a
1Yn/a
ATR %12.4%
52w lowhigh16.5% off high

What 6467 does

No business profile yet.

6467 at a glance

Size 6467 (6467.TW) is a Taiwan Health Care company (Pharmaceuticals: Major) with a market value of $368M, the 546th largest of 648 Taiwan companies the cockpit tracks. Shares closed at NT$224.50 on 18 Nov 2026.

Growth The operating margin is -2,617.6% (peer median -2.6%).

Valuation It trades at 1,407.9× enterprise value to sales against a peer median of 3.7× (most expensive of 18).

Next results Next results expected around 2 Dec 2026 (exchange calendar; dates can move).

6467 financials

Reported figures in TWD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenuen/aNT$8.41MNT$0NT$1.07MNT$6.36M
Revenue growth——-100%-83%—
Gross profitn/a-NT$2.08M-NT$6.99M-NT$7.82M-NT$3.88M
EBITDAn/a-NT$211M-NT$163M-NT$113M-NT$57.8M
Net incomen/a-NT$214M-NT$167M-NT$121M-NT$66.3M
Free cash flown/a-NT$209M-NT$166M-NT$107M-NT$63.6M
Capital expendituren/aNT$6.31MNT$8.82MNT$2.89MNT$829,000
Total debtNT$8.56MNT$11.3MNT$16.7MNT$53.6MNT$32.0M

Quarterly statements and history in the cockpit →

6467 competitors and peer comparison

How 6467 compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

6467 against its 20 peers (data as of 18 Nov 2026)
Measure6467.TWPeer medianRank in peer set
Distance from 52-week high-16.5%-41.3%3rd highest of 21
Operating margin-2,617.6%-2.6%lowest of 18
EV / Sales1,407.9×3.7×most expensive of 18

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
6467 6467.TWTaiwan$368Mn/an/a-2,618%1,407.9×n/an/a
Guangdong Lifestrong Pharmacy 301111.SZChina$368M-33%+7%-2%7.2×n/an/a
MapLight Therapeutics MPLTUnited States$370M-76%n/an/an/an/an/a
Tiansheng Pharmaceutical 002872.SZChina$371M-1%-1%-13%4.9×22.2%-15.7%
ARS Pharmaceuticals SPRYUnited States$371M-53%-14%-162%2.9×n/an/a
Pharmicell 005690.KSSouth Korea$364M-55%+46%32%3.0×-7.9%+24.8%
Puma Biotechnology PBYIUnited States$373M+3%+9%11%1.2×0.1%+0.3%
Tuoxin Pharmaceutical 301089.SZChina$363M-28%+17%-20%5.3×n/an/a
Jiangsu Bioperfectus Technologies 688399.SSChina$374M-51%-8%-23%4.4×n/an/a
Unichem Laboratories UNICHEMLAB.NSIndia$361M+28%+6%5%1.6×n/an/a
KYORIN Pharmaceutical 4569.TJapan$360M-22%-6%2%0.5×6.7%+4.2%
Opus Genetics IRDUnited States$379M-22%-46%-778%41.2×n/an/a
JCR Pharmaceuticals 4552.TJapan$379M-5%+3%-14%2.9×n/an/a
Anhui Fengyuan Pharmaceutical 000153.SZChina$355M-17%-24%3%1.1×3.6%+3.1%
ASKA Pharmaceutical 4886.TJapan$354M-24%+11%n/an/an/an/a
Lifecome Biochemistry 002868.SZChina$384M-54%-23%-3%6.2×n/an/a
SanBio 4592.TJapan$386M-55%n/an/an/an/an/a
Gansu Longshenrongfa Pharmaceutical Industry 300534.SZChina$386M-2%-21%8%3.7×20.9%+28.2%
Shukra Pharmaceuticals SHUKRAPHAR.NSIndia$387Mn/a+222%54%32.0×n/an/a
iX Biopharma 42C.SISingapore$387M+28%-12%-140%71.6×n/an/a
Guizhou Yibai Pharmaceutical 600594.SSChina$351M-23%-26%-15%1.9×8.0%-11.3%

Questions

Which companies are 6467's closest peers?
The cockpit's peer set: Guangdong Lifestrong Pharmacy (301111.SZ), MapLight Therapeutics (MPLT), Tiansheng Pharmaceutical (002872.SZ), ARS Pharmaceuticals (SPRY), Pharmicell (005690.KS), Puma Biotechnology (PBYI), Tuoxin Pharmaceutical (301089.SZ), Jiangsu Bioperfectus Technologies (688399.SS).
Is 6467 expensive compared with its peers?
On ev / sales it trades at 1,407.9× against a peer median of 3.7×, most expensive of 18 in its peer set.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.